Alpha 2.0
Login Register
» Articles » PMID: 38650710

Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital, North West Ethiopia

Overview
Journal Integr Pharm Res Pract
Date 2024 Apr 23
PMID 38650710
Authors
Bantayehu Addis Tegegne
Agumas Alemu Alehegn
Mengistie Kassahun
Affiliations
Soon will be listed here.
Abstract

Background: A key strategy for quality improvement is drug use evaluation, which looks at the safe, appropriate use of medication principles. Tenofovir/Lamivudine/Dolutegravir (TLD-FDC) usage has not yet been sufficiently examined in published literature. The purpose of this study was to assess how TLD were used by HIV-positive patients Using WHO drug use evaluation standards in Lumame Primary Hospital, North West Ethiopia.

Methods: Using WHO drug use evaluation standards, a retrospective study design was used to evaluate the appropriateness of TLD use. Systematic random sampling was utilized to gather patient medical records containing TLD. Accordingly, 100 records that met the inclusion criteria were selected and reviewed between April 1 and 15, 2021. Five criteria, namely, indication, dose, contraindication, drug interaction, and TLD safety monitoring were used to evaluate the appropriateness of TLD utilization.

Results: 80% of patients were transited to TLD from other regimens. The median time on TLD was found to be 13 months with 9 months to 18 months IQR. The latest CD4 count as well as CD4 count at the initiation or transition of TLD was not done for 75% and 89% of the patients, respectively. 3/4 (75%) of the patients were found to have a scheduled medication refill history. TLD dosing, indications, and contraindications were found to be 100% appropriate. No, TLD safety monitoring tests were done for 21% of the patients in this study. However, viral load, liver/kidney function, and serum creatinine tests were done for 77% (95% CI: 74%-79%), 5% (95% CI: 2%-8%), and 14% (95% CI: 11%-17%) of the patients, respectively. More over, In 93% (95% CI: 91%-95%) of the patients, the TLD interaction was appropriate; in 7%, it was not. All recording, documenting, and reporting technologies were available and used efficiently, except for the Electronic Dispensing Tool.

Conclusion: Generally, good adherence to national and WHO guidelines was obtained regarding dose, indication, and contraindications. However, improvement in safety monitoring tests and CPT utilization is recommended. Drug interactions satisfied the majority of the criteria's threshold, while certain standards were not followed.

References
1.
. Approved: The Joint Commission's hospital performance measurement implementation plan through 2008. Jt Comm Perspect. 2007; 27(3):1, 3-5. View
2.
Lemay J, Waheedi M, Al-Sharqawi S, Bayoud T . Medication adherence in chronic illness: do beliefs about medications play a role?. Patient Prefer Adherence. 2018; 12:1687-1698. PMC: 6130270. DOI: 10.2147/PPA.S169236. View
3.
Tassew S, Abraha H, Gidey K, Gebre A . Assessment of drug use pattern using WHO core drug use indicators in selected general hospitals: a cross-sectional study in Tigray region, Ethiopia. BMJ Open. 2021; 11(10):e045805. PMC: 8552154. DOI: 10.1136/bmjopen-2020-045805. View
4.
Lu L, Li X, Liu X, Han Y, Qiu Z, Song X . Comparison of Renal Function Biomarkers of Serum Creatinine and Cystatin C in HIV-Infected People on Dolutegravir-Containing Therapy. Infect Drug Resist. 2022; 15:1695-1706. PMC: 9005235. DOI: 10.2147/IDR.S347054. View
5.
Gupta R, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L . HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2017; 18(3):346-355. PMC: 5835664. DOI: 10.1016/S1473-3099(17)30702-8. View